

# Bradley Merrill Thompson Quoted in “FDA Promises a Draft Guidance for Change Control for Artificial Intelligence in 2021”

*BioWorld*

January 12, 2021 | Media Coverage

**Bradley Merrill Thompson**, Strategic Advisor with EBG Advisors and Member of the Firm at Epstein Becker Green, was quoted in *BioWorld*, in “FDA Promises a Draft Guidance for Change Control for Artificial Intelligence in 2021,” by Mark McCarty. (*Read the full version – subscription required.*)

Following is an excerpt:

The U.S. FDA has issued an action plan for regulation of artificial intelligence and machine learning (AI, ML), which includes issuance of a draft guidance for change control for adaptive algorithms. There is no guarantee a final guidance will emerge before 2022, however, leaving developers with another year – perhaps longer – of uncertainty as to how to handle change control for their algorithms. ...

Bradley Merrill Thompson of Epstein Becker Green told *BioWorld* at the time that a press release by then-FDA commissioner Scott Gottlieb avoided any mention of a need for new statutory authority. Gottlieb had already tendered his resignation, however, and thus any such remarks might have been treated with skepticism.

## People



Bradley Merrill Thompson  
Strategic Advisor  
Artificial Intelligence  
202-861-1817  
bthompson@ebglaw.com

## Focus Areas

### Services

Artificial Intelligence